Articles

This section provides a brief overview of FDA news related to cancer drugs, including new drugs and new indications approved by the FDA between June 22, 2022, and July 14, 2022. Read More ›

Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions. Read More ›

Study evaluates factors that may help determine whether a patient with advanced non–small-cell lung cancer may benefit from the use of immune checkpoint inhibitors. Read More ›

In patients with non–small-cell lung cancer, KRAS G12C mutation is associated with female sex, smoking, and adenocarcinoma and the risk of development of central nervous system metastasis. Read More ›

Analysis reveals factors associated with the development of immune-related adverse events in patients with advanced non–small-cell lung cancer treated with immunotherapy. Read More ›

The Abramson Cancer Center at Penn Medicine Chester County Hospital, based in West Chester, PA, is a Commission on Cancer–accredited oncology program dedicated to providing patients with accessible state-of-the-art care in a community hospital setting. Read More ›

Patients with cancer and immunoglobulin deficiency have compromised immune systems–based response to COVID-19 vaccines. A team of researchers in Germany has developed a multipeptide COVID-19 vaccine that boosts immunity in immunocompromised patients, according to results of a phase 1/2 trial reported at the 2022 American Association for Cancer Research annual meeting. Read More ›

On the second day of the 2022 Cholangiocarcinoma Foundation annual meeting, Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Harvard Medical School, and Lead, Liver Cancer Research Program, Massachusetts General Hospital Cancer Center, Boston, presented a clinical update on emerging systemic therapies in cholangiocarcinoma (CCA). Read More ›